{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:47:42Z","timestamp":1783108062014,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Testosterone therapy represents the cornerstone of gender affirming hormone therapy (GAHT) among t-AFAB (transgender Assigned Female At Birth) people. Minoxidil is a vasodilator drug approved for topical use for the treatment of androgenetic alopecia. The aim of the present study was to evaluate the efficacy of topical minoxidil in enhancing beard growth in a group of t-AFAB people on GAHT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixteen t-AFAB individuals with an incomplete beard development, on GAHT for at least 6\u00a0months, were enrolled. Topical minoxidil was applied to the interested facial areas. Before starting (T0), after 3 (T3) and 6 (T6) months, we evaluated facial hair growth using the Ferriman-Gallwey modified score (FGm).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Subjects were 26 (2.7) years old and on GAHT for 18.5 [15\u201354] months; using a paired match evaluation, a statistically significant facial hair growth was observed over time, in particular at T6 (median upper lip FGm 3.5 [3\u20134] vs 2 [1\u20132] at T0 and chin FGm\u00a04 [3.25\u20134] vs 1 [1\u20132] at T0; p\u2009\u2264\u20090.002). Comparing the minoxidil group with a control group (n\u2009=\u200916) matched for age and BMI who developed a full-grown beard only with GAHT, a logistic multivariable analysis identified hirsutism before GAHT was independently positively associated with the development of a full beard [OR 15.22 (95% CI 1.46\u2013158.82); p\u2009=\u20090.023].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first study demonstrating the efficacy of topical minoxidil in enhancing facial hair growth among t-AFAB people on GAHT. Further studies will be necessary to assess whether the obtained improvements will persist after discontinuing the medication.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-024-02373-8","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T18:01:16Z","timestamp":1713722476000},"page":"2843-2850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of topical minoxidil in enhancing beard growth in a group of transgender assigned female at birth individuals on gender affirming hormone therapy"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7567-4753","authenticated-orcid":false,"given":"L.","family":"Marinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bichiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cagnina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Castella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,21]]},"reference":[{"issue":"2","key":"2373_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.24869\/PSYD.2020.145","volume":"32","author":"T Dakic","year":"2020","unstructured":"Dakic T (2020) New perspectives on transgender health in the forthcoming 11th revision of the international statistical classification of diseases and related health problems: an overview of gender incongruence \u2014 depathologization, considerations and recommendations for practitioners. Psychiatr Danub 32(2):145\u2013150. https:\/\/doi.org\/10.24869\/PSYD.2020.145","journal-title":"Psychiatr Danub"},{"issue":"Suppl 1","key":"2373_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","volume":"23","author":"E Coleman","year":"2022","unstructured":"Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB, Ettner R, Fraser L, Goodman M, Green J, Hancock AB, Johnson TW, Karasic DH, Knudson GA, Leibowitz SF, Meyer-Bahlburg HFL, Monstrey SJ, Motmans J, Nahata L, Arcelus J (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgender Health 23(Suppl 1):S1\u2013S259. https:\/\/doi.org\/10.1080\/26895269.2022.2100644","journal-title":"Int J Transgender Health"},{"issue":"3","key":"2373_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/S40618-021-01694-2","volume":"45","author":"AD Fisher","year":"2022","unstructured":"Fisher AD, Senofonte G, Cocchetti C, Guercio G, Lingiardi V, Meriggiola MC, Mosconi M, Motta G, Ristori J, Speranza AM, Pierdominici M, Maggi M, Corona G, Lombardo F (2022) SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people. J Endocrinol Invest 45(3):657\u2013673. https:\/\/doi.org\/10.1007\/S40618-021-01694-2","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2373_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/J.JSXM.2019.12.020","volume":"17","author":"J Defreyne","year":"2020","unstructured":"Defreyne J, Elaut E, Kreukels B, Fisher AD, Castellini G, Staphorsius A, Den Heijer M, Heylens G, T\u2019Sjoen G (2020) Sexual desire changes in transgender individuals upon initiation of hormone treatment: results from the longitudinal european network for the investigation of gender incongruence. J Sex Med 17(4):812\u2013825. https:\/\/doi.org\/10.1016\/J.JSXM.2019.12.020","journal-title":"J Sex Med"},{"issue":"8","key":"2373_CR5","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1210\/JCEM.85.8.6710","volume":"85","author":"EJ Giltay","year":"2000","unstructured":"Giltay EJ, Gooren LJG (2000) Effects of sex steroid deprivation\/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 85(8):2913\u20132921. https:\/\/doi.org\/10.1210\/JCEM.85.8.6710","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2373_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/J.JAAD.2020.02.053","volume":"83","author":"H Yeung","year":"2020","unstructured":"Yeung H, Ragmanauskaite L, Zhang Q, Kim J, Tangpricha V, Getahun D, Silverberg MJ, Goodman M (2020) Prevalence of moderate to severe acne in transgender adults: a cross-sectional survey. J Am Acad Dermatol 83(5):1450\u20131452. https:\/\/doi.org\/10.1016\/J.JAAD.2020.02.053","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2373_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1210\/ER.2018-00011","volume":"40","author":"G T\u2019Sjoen","year":"2019","unstructured":"T\u2019Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V (2019) Endocrinology of transgender medicine. Endocr Rev 40(1):97\u2013117. https:\/\/doi.org\/10.1210\/ER.2018-00011","journal-title":"Endocr Rev"},{"issue":"11","key":"2373_CR8","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1210\/JC.2016-1276","volume":"101","author":"AD Fisher","year":"2016","unstructured":"Fisher AD, Castellini G, Ristori J, Casale H, Cassioli E, Sensi C, Fanni E, Amato AML, Bettini E, Mosconi M, D\u00e8ttore D, Ricca V, Maggi M (2016) Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data. J Clin Endocrinol Metab 101(11):4260\u20134269. https:\/\/doi.org\/10.1210\/JC.2016-1276","journal-title":"J Clin Endocrinol Metab"},{"key":"2373_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/J.BODYIM.2016.06.004","volume":"18","author":"JK McGuire","year":"2016","unstructured":"McGuire JK, Doty JL, Catalpa JM, Ola C (2016) Body image in transgender young people: findings from a qualitative, community based study. Body Image 18:96\u2013107. https:\/\/doi.org\/10.1016\/J.BODYIM.2016.06.004","journal-title":"Body Image"},{"issue":"16","key":"2373_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1056\/NEJM198010163031607","volume":"303","author":"J Koch-Weser","year":"1980","unstructured":"Koch-Weser J, Pettinger WA (1980) Minoxidil and the treatment of severe hypertension. N Engl J Med 303(16):922\u2013926. https:\/\/doi.org\/10.1056\/NEJM198010163031607","journal-title":"N Engl J Med"},{"issue":"5","key":"2373_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/J.1524-6175.2004.03585.X","volume":"6","author":"DA Sica","year":"2004","unstructured":"Sica DA (2004) Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich, Conn) 6(5):283\u2013287. https:\/\/doi.org\/10.1111\/J.1524-6175.2004.03585.X","journal-title":"J Clin Hypertens (Greenwich, Conn)"},{"key":"2373_CR12","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2147\/DDDT.S214907","volume":"13","author":"P Suchonwanit","year":"2019","unstructured":"Suchonwanit P, Thammarucha S, Leerunyakul K (2019) Minoxidil and its use in hair disorders: a review. Drug Des Dev Ther 13:2777\u20132786. https:\/\/doi.org\/10.2147\/DDDT.S214907","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"2373_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/1523-1747.EP12277095","volume":"92","author":"AE Buhl","year":"1989","unstructured":"Buhl AE, Waldon DJ, Kawabe T, Holland JM (1989) Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol 92(3):315\u2013320. https:\/\/doi.org\/10.1111\/1523-1747.EP12277095","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2373_CR14","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1096\/FJ.07-099424","volume":"22","author":"K Shorter","year":"2008","unstructured":"Shorter K, Farjo NP, Picksley SM, Randall VA (2008) Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J: Off Publ Fed Am Soc Exp Biol 22(6):1725\u20131736. https:\/\/doi.org\/10.1096\/FJ.07-099424","journal-title":"FASEB J: Off Publ Fed Am Soc Exp Biol"},{"issue":"8","key":"2373_CR15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/1346-8138.13312","volume":"43","author":"S Ingprasert","year":"2016","unstructured":"Ingprasert S, Tanglertsampan C, Tangphianphan N, Reanmanee C (2016) Efficacy and safety of minoxidil 3% lotion for beard enhancement: a randomized, double-masked, placebo-controlled study. J Dermatol 43(8):968\u2013969. https:\/\/doi.org\/10.1111\/1346-8138.13312","journal-title":"J Dermatol"},{"key":"2373_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2021.725269","author":"KC Pang","year":"2021","unstructured":"Pang KC, Nguyen TP, Upreti R (2021) Case report: successful use of minoxidil to promote facial hair growth in an adolescent transgender male. Front Endocrinol. https:\/\/doi.org\/10.3389\/FENDO.2021.725269","journal-title":"Front Endocrinol"},{"issue":"4","key":"2373_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1210\/jc.2018-00241","volume":"103","author":"AK Martin","year":"2018","unstructured":"Martin AK, Anderson RR, Chang RJ, Ehrmann DA, Lobo AR, Murad MH, Pugeat MM, Rosenfield RL (2018) Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(4):1233\u20131257","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2373_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/J.1523-1747.1998.00396.X","volume":"111","author":"MJ Thornton","year":"1998","unstructured":"Thornton MJ, Hamada K, Messenger AG, Randall VA (1998) Androgen-dependent beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells. J Invest Dermatol 111(5):727\u2013732. https:\/\/doi.org\/10.1046\/J.1523-1747.1998.00396.X","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2373_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/JSM.12366","volume":"11","author":"K Wierckx","year":"2014","unstructured":"Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, Kaufman JM, T\u2019Sjoen G (2014) Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med 11(1):222\u2013229. https:\/\/doi.org\/10.1111\/JSM.12366","journal-title":"J Sex Med"},{"issue":"12","key":"2373_CR20","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/JSM.12698","volume":"11","author":"C Pelusi","year":"2014","unstructured":"Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, Battista G, Venturoli S, Meriggiola MC (2014) Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med 11(12):3002\u20133011. https:\/\/doi.org\/10.1111\/JSM.12698","journal-title":"J Sex Med"},{"issue":"9","key":"2373_CR21","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1210\/JC.2007-0746","volume":"92","author":"A Mueller","year":"2007","unstructured":"Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R (2007) Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 92(9):3470\u20133475. https:\/\/doi.org\/10.1210\/JC.2007-0746","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2373_CR22","doi-asserted-by":"publisher","first-page":"100306","DOI":"10.1016\/J.ESXM.2020.100306","volume":"9","author":"T Kirisawa","year":"2021","unstructured":"Kirisawa T, Ichihara K, Sakai Y, Morooka D, Iyoki T, Masumori N (2021) Physical and psychological effects of gender-affirming hormonal treatment using intramuscular testosterone enanthate in japanese transgender men. Sex Med 9(2):100306\u2013100306. https:\/\/doi.org\/10.1016\/J.ESXM.2020.100306","journal-title":"Sex Med"},{"key":"2373_CR23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0112","author":"MC Madsen","year":"2022","unstructured":"Madsen MC, Den Heijer M, Pees C, Biermasz NR, Bakker LEH (2022) Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations. Endocr Connect. https:\/\/doi.org\/10.1530\/EC-22-0112","journal-title":"Endocr Connect"},{"issue":"5","key":"2373_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/J.1600-0536.1995.TB00798.X","volume":"32","author":"H Ebner","year":"1995","unstructured":"Ebner H, M\u00fcller E (1995) Allergic contact dermatitis from minoxidil. Contact Dermat 32(5):316\u2013317. https:\/\/doi.org\/10.1111\/J.1600-0536.1995.TB00798.X","journal-title":"Contact Dermat"},{"issue":"12","key":"2373_CR25","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1111\/JOCD.14537","volume":"20","author":"MS Nestor","year":"2021","unstructured":"Nestor MS, Ablon G, Gade A, Han H, Fischer DL (2021) Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol 20(12):3759\u20133781. https:\/\/doi.org\/10.1111\/JOCD.14537","journal-title":"J Cosmet Dermatol"},{"issue":"24","key":"2373_CR26","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1056\/NEJMCP033496","volume":"353","author":"RL Rosenfield","year":"2005","unstructured":"Rosenfield RL (2005) Clinical practice. Hirsutism. N Engl J Med 353(24):2578\u20132588. https:\/\/doi.org\/10.1056\/NEJMCP033496","journal-title":"N Engl J Med"},{"issue":"2","key":"2373_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/ARCHDERM.1987.01660260079018","volume":"123","author":"SB Reingold","year":"1987","unstructured":"Reingold SB, Rosenfield RL (1987) the relationship of mild hirsutism or acne in women to androgens. Arch Dermatol 123(2):209\u2013212. https:\/\/doi.org\/10.1001\/ARCHDERM.1987.01660260079018","journal-title":"Arch Dermatol"},{"issue":"2","key":"2373_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1210\/JCEM-57-2-393","volume":"57","author":"RA Lobo","year":"1983","unstructured":"Lobo RA, Goebelsmann U, Horton R (1983) Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 57(2):393\u2013397. https:\/\/doi.org\/10.1210\/JCEM-57-2-393","journal-title":"J Clin Endocrinol Metab"},{"key":"2373_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.TALANTA.2022.124218","author":"F Ponzetto","year":"2023","unstructured":"Ponzetto F, Parasiliti-Caprino M, Gesmundo I, Marinelli L, Nonnato A, Nicoli R, Kuuranne T, Mengozzi G, Ghigo E, Settanni F (2023) Single-run UHPLC-MS\/MS method for simultaneous quantification of endogenous steroids and their phase II metabolites in serum for anti-doping purposes. Talanta. https:\/\/doi.org\/10.1016\/J.TALANTA.2022.124218","journal-title":"Talanta"},{"key":"2373_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/JCM9061609","author":"C Cocchetti","year":"2020","unstructured":"Cocchetti C, Ristori J, Romani A, Maggi M, Fisher AD (2020) Hormonal treatment strategies tailored to non-binary transgender individuals. J Clin Med. https:\/\/doi.org\/10.3390\/JCM9061609","journal-title":"J Clin Med"},{"key":"2373_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.COPSYC.2022.101499","volume":"48","author":"ZC Schudson","year":"2022","unstructured":"Schudson ZC, Morgenroth T (2022) Non-binary gender\/sex identities. Curr Opin Psychol 48:101499. https:\/\/doi.org\/10.1016\/J.COPSYC.2022.101499","journal-title":"Curr Opin Psychol"},{"key":"2373_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES10092279","author":"JY Choi","year":"2022","unstructured":"Choi JY, Kim TJ (2022) Fertility preservation and reproductive potential in transgender and gender fluid population. Biomedicines. https:\/\/doi.org\/10.3390\/BIOMEDICINES10092279","journal-title":"Biomedicines"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02373-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02373-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02373-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T10:04:09Z","timestamp":1728900249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02373-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,21]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02373-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,21]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all subjects involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The research is involving human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}